A Clinical study to which Anti-emetic effect of change of 5-HT3RA is evaluated by using MAT in MEC for gastrointestinal cancer.
Not Applicable
- Conditions
- Gastric and Colorectal Cancer
- Registration Number
- JPRN-UMIN000004133
- Lead Sponsor
- Kochi Health Sciences Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1) The change (The change of Dose is included) in the chemotherapeutic regimen is scheduled before and after the change of 5- HT3RA. 2) Hypersensitivity or severe drug allergy for Aloxi or other 5-HT3RA. 3) Hypersensitivity or severe drug allergy for dexamethasone. 4) Any other patient whom the physician in charge of the study judges to be not eligible
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The level of each observation point of the nausea and vomiting before and after 5- HT3RA change is evaluated by MAT.
- Secondary Outcome Measures
Name Time Method